Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

Share Price is delayed by 15 minutes
Get Live Data
500.00    12.60 (2.59%)
Bid:
500.00
Ask:
501.00
Spread: 1.00 (0.20%)
Market Cap: £1.35b
CHG Live PriceLast checked at - London Stock Exchange

Intraday Chemring Share Chart

Directorate Change

24 Jun 2014 07:00

RNS Number : 3280K
Chemring Group PLC
24 June 2014
Β 

ο»Ώ

Β FOR IMMEDIATE RELEASE 24 JUNE 2014

Β 

CHEMRING GROUP PLC

Β 

Directorate change

Β 

Michael Flowers appointed Group Chief Executive

Β 

Chemring Group PLC ("Chemring" or "the Group") announces that Michael Flowers has been appointed Group Chief Executive with immediate effect.Β Michael joined Chemring in 2006 and prior to today's appointment was Group Director, Countermeasures and a member of Chemring's Executive Committee.

Β 

Michael Flowers has spent 13 years in senior management positions within the defence industry.Β He previously served as an officer in the Australian Army for 22 years and was a graduate of the Australian Command and Staff College and the British Royal Military College of Science.Β After leaving the army, he was a senior manager at BAE Systems from 2001 to 2006, in programme and project management roles.

Β 

From 2006, he was Managing Director, Chemring Australia, where he established a state of the art countermeasures manufacturing facility and delivered substantial growth in the defence portfolio. In 2013, he was appointed Group Director, Munitions, with responsibility for Chemring's European munitions business. Michael led the successful sale of the European munitions business following the 2013 strategic review, working closely with Chemring's Board and advisers to negotiate and complete the disposal in May 2014.

Β 

Mark Papworth has stepped down from the Board of Chemring with immediate effect.Β 

Β 

Peter Hickson, Chairman of Chemring, said:

Β 

"Michael Flowers has a proven track record, both within the international defence industry and within Chemring, where he led our Australian business through a successful period of growth and, more recently, managed the complex disposal process of the European munitions business. Michael is extremely knowledgeable about our markets and is well qualified to lead Chemring as we capitalise on our world leading technologies in Countermeasures, Sensors & Electronics and Energetic Systems.

Β 

Much has been achieved during Mark Papworth's tenure, including a significant reorganisation and refocusing of the Group and a substantial reduction in the cost baseΒ and we are grateful for his leadership during this period.

Β 

We are now moving from a period of critical and significant change to one where we must take maximum advantage of the stronger platform that has been created.Β To achieve this, a different set of skills is required in the role of Chief Executive, in particular extensive knowledge and understanding of the defence markets in which we operate."

Β 

Michael Flowers has a beneficial shareholding of 80,680 Chemring shares.

Β 

There is no further information to be disclosed pursuant to paragraph 9.6.13R of the UK Listing Rules in relation to Michael Flowers' appointment as a director of Chemring.

Β 

Ends

Β 

Β 

Β 

Β 

For further information, contact:

Β 

Chemring Group PLC 01489 881 880

Peter Hickson, Chairman

Steve Bowers, Finance Director

Rupert Pittman, Group Director of Communications and Investor Relations

Β 

MHP Communications 020 3128 8100

Andrew Jaques

John Olsen

James White

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
BOADDGDLSBDBGSX
Date   Source Headline
10th Dec 20257:00 amRNSTransaction in Own Shares
9th Dec 20254:23 pmRNSDirector/PDMR Shareholding
9th Dec 20257:00 amRNSResults for the year ended 31 October 2025
9th Dec 20257:00 amRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
5th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20257:00 amRNSTransaction in Own Shares
3rd Dec 20257:00 amRNSTransaction in Own Shares
2nd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20257:00 amRNSTotal Voting Rights
28th Nov 20257:00 amRNSTransaction in Own Shares
27th Nov 20257:00 amRNSTransaction in Own Shares
26th Nov 20257:00 amRNSTransaction in Own Shares
25th Nov 20257:00 amRNSTransaction in Own Shares
24th Nov 20257:00 amRNSTransaction in Own Shares
21st Nov 20257:00 amRNSTransaction in Own Shares
20th Nov 20257:00 amRNSTransaction in Own Shares
18th Nov 20253:52 pmRNSHolding(s) in Company
17th Nov 20257:00 amRNSTransaction in Own Shares
14th Nov 20257:16 amRNSDirector Declaration
10th Nov 20257:00 amRNSHolding(s) in Company
10th Nov 20257:00 amRNSPost-close and contract wins update
3rd Nov 20257:00 amRNSAppointment of Joint Corporate Broker
3rd Nov 20257:00 amRNSTotal Voting Rights
9th Oct 20252:54 pmRNSHolding(s) in Company
1st Oct 20257:00 amRNSTotal Voting Rights
9th Sep 202510:24 amRNSDirector/PDMR Shareholding
9th Sep 20259:55 amRNSHolding(s) in Company
1st Sep 20257:00 amRNSTotal Voting Rights
20th Aug 20253:49 pmRNSHolding(s) in Company
12th Aug 20252:02 pmRNSHolding(s) in Company
12th Aug 20257:00 amRNSAdditional Listing
1st Aug 20257:00 amRNSTotal Voting Rights
1st Jul 20257:00 amRNSTotal Voting Rights
30th Jun 20257:00 amRNSAcquisition of Landguard Systems
26th Jun 20257:00 amRNSNorwegian feasibility study
18th Jun 20257:00 amRNSBlock listing Interim Review
18th Jun 20257:00 amRNSBlock listing update
4th Jun 20257:00 amRNSTransaction in Own Shares
3rd Jun 20257:00 amRNSDirectorate Change
3rd Jun 20257:00 amRNSInterim Results
1st May 20259:15 amRNSTotal Voting Rights
29th Apr 20257:00 amRNSTransaction in Own Shares
28th Apr 20257:00 amRNSTransaction in Own Shares
25th Apr 20257:00 amRNSTransaction in Own Shares
24th Apr 20257:00 amRNSTransaction in Own Shares
23rd Apr 20257:00 amRNSTransaction in Own Shares
22nd Apr 20257:00 amRNSTransaction in Own Shares
17th Apr 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.